Tongshu gene has reached strategic cooperation with Ping An health to create a closed loop for accurate diagnosis and treatment of tumors

Recently, Tongshu Biotechnology Co., Ltd. (Tongshu gene) and Ping An Health Medical Technology Co., Ltd. (stock abbreviation "ping an good doctor", 1833. HK) officially reached a strategic cooperation. The two sides will focus on the field of cancer precision medicine and jointly build the whole course management service for cancer patients. At present, Ping An Health has its own medical team of nearly 2000 people, a total of 46500 external doctors and experts, and has built more than 800 famous medical studios. Tongshu gene liquid biopsy technology and products have achieved large-scale clinical application in many cancer fields such as lung cancer, gastric cancer and urinary tumor. The detection service network covers more than 500 core hospitals in five regions of the country. Its self-developed microsatellite instability (MSI) detection kit broke the domestic standardized detection gap in this field and won the first class III medical device registration certificate. According to the strategic cooperation agreement, the two sides will give full play to their respective advantages in cooperation, create innovative service models and solutions for accurate diagnosis and treatment of tumors, and provide users with medical and health management services. It is reported that the two sides will also cooperate in commercial insurance. Ping An Health's "insurance + medical health", family doctor membership and o2o medical service model will provide support for the implementation of strategic cooperation. In addition, the two sides will also cooperate in doctor training, pharmaceutical retail and other aspects, and respond to the call of the international lung cancer concern month to launch online public welfare free clinic activities for cancer and lung cancer patients.